Growth arrest and DNA-damage-inducible protein GADD45 alpha (Gadd45a) is a protein involved in the p38 MAP kinase signaling pathway. Inventors at the NCI have developed a 15 amino acid peptide fragment of Gadd45a that retains the functionality of Gadd45a by inhibiting enzymatic activity of tyrosine-323-phosphorylaled p38 in vitro. The peptide is modified to make it cell permeable and exhibits minimal toxicity in vitro. The fragment readily penetrates T cells to inhibit (a) proliferation in response to T cell receptor-mediated stimulation; (b) skewing of T cells to Th I and Th 17 cells; and (c) inflammatory cytokine production. As a result, this fragment has anti-inflammatory properties and has potential as a therapeutic for inflammatory autoimmune conditions or inflammatory cancers, such as pancreatic cancer.
- Treatment for inflammatory autoimmune conditions or inflammatory cancers, such as pancreatic cancer.
- Minimal cellular toxicity
- U.S. Patent Issued: U.S. Patent Number 9359418